{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:15Z","timestamp":1791357315217,"version":"4.3.1"},"reference-count":45,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>\n                    Our aim was to review the efficacy, safety, and pharmacology of brexanolone (Zulresso), a new antidepressant with a novel mechanism of action, in the treatment of postpartum depression (\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    ). Pertinent data and information were obtained via PubMed (1993 to August 2018). Articles published in English that evaluated the safety and efficacy of brexanolone and other off\u2010label\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    treatments were included. Literature regarding epidemiology and pathophysiology of\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    was also selected. Brexanolone, administered as an intravenous infusion over 60\u00a0hours, produced a statistically significant and clinically meaningful reduction in Hamilton Depression Rating Scale (\n                    <jats:styled-content style=\"fixed-case\">HAM<\/jats:styled-content>\n                    \u2010D) scores compared with placebo at both 60 and 90\u00a0\u03bcg\/kg\/hour in patients with moderate to severe\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    . Brexanolone groups had higher response and remission rates compared with placebo. Common adverse effects were somnolence, dizziness, and headache. A small percentage (4%) of patients required cessation of therapy due to excessive sedation or loss of consciousness. Although the evidence for brexanolone as a novel treatment for\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    looks promising, a Risk Evaluation and Mitigation Strategies (\n                    <jats:styled-content style=\"fixed-case\">REMS<\/jats:styled-content>\n                    ) program requirement and the logistics of prolonged infusions serve as barriers to treatment. A discussion of these obstacles as well as pharmacokinetics, monitoring, and dosing is provided. Brexanolone is a novel antidepressant indicated for the treatment of\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    . Clinical trials demonstrated that brexanolone significantly reduces depression scores in women with moderate to severe\n                    <jats:styled-content style=\"fixed-case\">PPD<\/jats:styled-content>\n                    . Due to risk of oversedation and loss of consciousness, a\n                    <jats:styled-content style=\"fixed-case\">REMS<\/jats:styled-content>\n                    program will be put in place to mitigate the risk of adverse events.\n                  <\/jats:p>","DOI":"10.1002\/phar.2331","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T17:58:29Z","timestamp":1568311109000},"page":"1105-1112","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-0243","authenticated-orcid":false,"given":"Lauren D.","family":"Leader","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Michigan Medicine Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Michigan Medicine Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Michigan Medicine Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Building U.S.Capacity to Review and Prevent Maternal Deaths. Report from nine maternal mortality review committees; 2018. Available fromhttp:\/\/reviewtoaction.org\/Report_from_Nine_MMRCs. Accessed April 30 2019."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596.dsm04"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1856"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6606a1"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004883"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.09.007"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001452"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2004.09.025"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2012.3926"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.201"},{"issue":"1","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1139\/jpn.0704","article-title":"Platelet serotonin levels support depression scores for women with postpartum depression","volume":"32","author":"Maurer\u2010Spurej E","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051095"},{"issue":"5","key":"e_1_2_12_14_1","first-page":"1912","article-title":"Hypothalamic corticotropin\u2010releasing hormone suppression during the postpartum period: implications for the increase in psychiatric manifestations at this time","volume":"1","author":"Magiakou MA","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970903144038"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.07.013"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2018.04.024"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S62912"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31264-3"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31551-4"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.1.57"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/imhj.21450"},{"key":"e_1_2_12_23_1","unstructured":"Zulresso\u2122[package insert].Cambridge MA;Sage Therapeutics Inc.;2019."},{"key":"e_1_2_12_24_1","unstructured":"Zulresso REMS Training for Healthcare Settings. Available fromhttps:\/\/www.zulressorems.com\/#Public\/Resources. Accessed May 24 2019."},{"key":"e_1_2_12_25_1","unstructured":"NASMHPD.Trend in psychiatric inpatient capacity United States and each state 1970 to 2014;2017:4\u20135."},{"issue":"2","key":"e_1_2_12_26_1","first-page":"CD002018","article-title":"Antidepressant treatment for postnatal depression [review]","author":"Molyneaux E","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867414565474"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3316-1"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07117"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14430"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0420"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000227706.56870.dd"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0913"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7085.932"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.10.361"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.8.1273a"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/depr.3050030109"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1739"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31826867c9"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0803"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316656297"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705005079"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-005-0071-2"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91414-2"},{"issue":"10","key":"e_1_2_12_45_1","first-page":"852","article-title":"Identification and management of peripartum depression","volume":"93","author":"Langan RC","year":"2016","journal-title":"Am Fam Physician"},{"key":"e_1_2_12_46_1","unstructured":"Centers for Disease Control and Prevention National Survey of Family Growth 2006\u20132010. Analysis conducted by the Maternal and Child Health Epidemiology and Statistics Program."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:39:56Z","timestamp":1761068396000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/phar.2331"],"URL":"https:\/\/doi.org\/10.1002\/phar.2331","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"2019-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}